Discovery of new biomarkers/validation/technologies
Among hundreds of thousands of cancer biomarkers have been discovered, only few of them have been approved during the past two decades by the FDA for monitoring response, surveillance, or recurrence of cancer. To be a clinically applicable and reliable biomarker, it must be of value for informing clinical decision-making to improve the patient outcome. Initially, CB have to distinguish between people with cancer and those without. In fact, many biomarkers do not achieve beyond this point because the investigators are either unable to develop robust, accurate assay methods, or this biomarker lacks sufficient sensitivity and/or specificity. Actually, there was very low rate (0.1%) of successful clinical translation of biomarker. Developing new cancer biomarkers has been formulated in stepwise manner. About 15 years ago, Hammond and Taube proposed an approach for CB development starting from discovering the marker, developing an assay method for assessment, analyzing its clinical potential preliminarily, standardization of its assay, and finally validation of such biomarker for clinical use.
Related Conference of Discovery of new biomarkers/validation/technologies
Discovery of new biomarkers/validation/technologies Conference Speakers
Recommended Sessions
- Biomarkers & Next-Generation Sequencing
- Biomarkers based on epidemiological investigations
- Biomarkers for Cancer Diagnosis
- Biomarkers in Drug discovery and development
- Biomarkers of Cardiovascular disorders
- Discovery of new biomarkers/validation/technologies
- Entrepreneur Investments Meet
- Imaging Technologies and Diagnostic tests of Biomarkers
- Biomarkers for Early Diagnosis and Prognosis
- Biomarkers for non-cancerous diseases
- Biomarkers in Diagnosis: Challenges and Approaches
- Biomarkers in Disease Treatment
- Biomarkers in Immune-Oncology
- Biomarkers of Disorders of the Nervous System
- Biomarkers: Validation & Verification
- Clinical and Biomedical Engineering
- Clinical Research & Biomarkers
- Genomic Biomarkers in Clinical Development
Related Journals
Are you interested in
- Advances in Separation Techniques - ANALYTICA ACTA 2024 (France)
- Analytical Chemistry and Methodology - ANALYTICA ACTA 2024 (France)
- Analytical Technique for Clinical Chemistry - ANALYTICA ACTA 2024 (France)
- Analytical Technique for Thermal analysis - ANALYTICA ACTA 2024 (France)
- Bioanalytical Methodology - ANALYTICA ACTA 2024 (France)
- Biochemistry - ANALYTICA ACTA 2024 (France)
- Biomarkers & Next-Generation Sequencing - Biomarkers 2024 (UK)
- Biomarkers based on epidemiological investigations - Biomarkers 2024 (UK)
- Biomarkers for Cancer Diagnosis - Biomarkers 2024 (UK)
- Biomarkers for Early Diagnosis and Prognosis - Biomarkers 2024 (UK)
- Biomarkers for non-cancerous diseases - Biomarkers 2024 (UK)
- Biomarkers in Diagnosis: Challenges and Approaches - Biomarkers 2024 (UK)
- Biomarkers in Disease Treatment - Biomarkers 2024 (UK)
- Biomarkers in Drug discovery and development - Biomarkers 2024 (UK)
- Biomarkers in Immune-Oncology - Biomarkers 2024 (UK)
- Biomarkers of Cardiovascular disorders - Biomarkers 2024 (UK)
- Biomarkers of Disorders of the Nervous System - Biomarkers 2024 (UK)
- Biomarkers: Validation & Verification - Biomarkers 2024 (UK)
- Biopolymers and Biomaterials - ANALYTICA ACTA 2024 (France)
- Chromatography - ANALYTICA ACTA 2024 (France)
- Clinical and Biomedical Engineering - Biomarkers 2024 (UK)
- Clinical Diagnostics Equipment and Kits - ANALYTICA ACTA 2024 (France)
- Clinical Research & Biomarkers - Biomarkers 2024 (UK)
- Discovery of new biomarkers/validation/technologies - Biomarkers 2024 (UK)
- Electrophoresis - ANALYTICA ACTA 2024 (France)
- Entrepreneur Investments Meet - Biomarkers 2024 (UK)
- Environmental Analytical Chemistry - ANALYTICA ACTA 2024 (France)
- Genomic Biomarkers in Clinical Development - Biomarkers 2024 (UK)
- Hyphenated Techniques - ANALYTICA ACTA 2024 (France)
- Imaging Technologies and Diagnostic tests of Biomarkers - Biomarkers 2024 (UK)
- Innovation in Food Analysis & Testing - ANALYTICA ACTA 2024 (France)
- Mass Spectrometry - ANALYTICA ACTA 2024 (France)
- Method development and validation - ANALYTICA ACTA 2024 (France)
- Microscopy - ANALYTICA ACTA 2024 (France)
- New Instrumentation and Equipment - ANALYTICA ACTA 2024 (France)
- Novel Optical Sensors and Biosensors - ANALYTICA ACTA 2024 (France)
- Pharmaceutical Analytics - ANALYTICA ACTA 2024 (France)
- Polymer Science and Material Science - ANALYTICA ACTA 2024 (France)
- Proteomics and its applications - ANALYTICA ACTA 2024 (France)
- Regulatory issues and Biosafety challenges in bioanalysis - ANALYTICA ACTA 2024 (France)
- Regulatory Issues and Biosafety Challenges in Bioanalysis - ANALYTICA ACTA 2024 (France)
- Spectroscopy - ANALYTICA ACTA 2024 (France)